Scolaris Content Display Scolaris Content Display

Anticonceptivos combinados: efectos sobre el peso

Contraer todo Desplegar todo

Resumen

Antecedentes

El aumento de peso a menudo se considera un efecto secundario de los anticonceptivos hormonales combinados y muchas mujeres y médicos creen que existe una asociación. La preocupación por el aumento de peso puede limitar el uso de este método anticonceptivo sumamente eficaz, ya que puede impedir el inicio del tratamiento y causar que las usuarias lo interrumpan de forma temprana. Sin embargo, no se ha establecido una relación causal entre los anticonceptivos combinados y el aumento de peso.

Objetivos

El objetivo de la revisión fue evaluar la asociación potencial entre el uso de métodos anticonceptivos combinados y las variaciones en el peso.

Métodos de búsqueda

En noviembre de 2013 se hicieron búsquedas de estudios de anticonceptivos combinados en las bases de datos electrónicas CENTRAL (The Cochrane Library), MEDLINE, POPLINE, EMBASE y LILACS, así como en ClinicalTrials.gov y en la International Clinical Trials Registry Platform (ICTRP). En la revisión inicial también se les escribió a investigadores y fabricantes conocidos para solicitarles información sobre otros ensayos publicados o no publicados que no se hubieran identificado en las búsquedas.

Criterios de selección

Fueron elegibles todos los ensayos controlados aleatorios en inglés si tenían al menos tres ciclos de tratamiento y compararon un anticonceptivo combinado con placebo o con un anticonceptivo combinado que difirió en el fármaco, la dosis, el régimen o la duración del estudio.

Obtención y análisis de los datos

Se evaluaron todos los títulos y resúmenes identificados a partir de las búsquedas bibliográficas. Los datos se introdujeron y analizaron con RevMan. Un segundo revisor comprobó los datos introducidos. Para los datos continuos la diferencia de medias y el intervalo de confianza (IC) del 95% para el cambio medio en el peso entre las mediciones iniciales y después del tratamiento se calcularon mediante un modelo de efectos fijos. Para los datos categóricos como la proporción de pacientes que ganaron o perdieron más de una cantidad específica de peso se calculó el odds ratio de Peto con el IC del 95%.

Resultados principales

Se encontraron 49 ensayos que cumplieron los criterios de inclusión. Los ensayos incluyeron 85 comparaciones de cambios en el peso para 52 pares de anticonceptivos distintos (o placebos). Los cuatro ensayos con un grupo placebo o ninguna intervención no encontraron pruebas que apoyaran una asociación causal entre los anticonceptivos combinados orales o un parche combinado cutáneo y el cambio en el peso. La mayoría de las comparaciones de diferentes anticonceptivos combinados no mostró diferencias significativas en el peso. Además, la interrupción de los anticonceptivos combinados debido al aumento de peso no difirió entre los grupos en los que se estudió este resultado.

Conclusiones de los autores

Las pruebas disponibles no son suficientes para determinar el efecto de los anticonceptivos combinados sobre el peso, aunque no hubo efectos importantes evidentes. Los ensayos para evaluar el vínculo entre los anticonceptivos combinados y el aumento de peso requieren un grupo placebo o sin hormonas para controlar otros factores, incluidos los cambios en el peso con el transcurso del tiempo.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Resumen en términos sencillos

Efecto de las píldoras y parches anticonceptivos sobre el peso

Se considera que el aumento de peso es un efecto secundario de los métodos de regulación de la natalidad. Muchas mujeres y profesionales sanitarios creen que las píldoras y los parches provocan aumento de peso. Las preocupaciones por el aumento de peso pueden limitar el uso de estos eficaces métodos de regulación de la natalidad. El temor al aumento de peso impide que algunas mujeres comiencen a utilizar la píldora o el parche. Las mujeres pueden dejar de utilizar la píldora porque piensan que les provoca aumento de peso. Esta revisión analizó los ensayos de píldoras o parches anticonceptivos donde se midió el peso de las mujeres.

En noviembre de 2013 se realizó una búsqueda computarizada de estudios de píldoras o parches que contenían dos tipos de hormonas. En la revisión inicial también se les escribió a investigadores y fabricantes para encontrar otros ensayos. Se incluyeron ensayos aleatorios en idioma inglés que tuvieran al menos tres ciclos de tratamiento. Los estudios también tenían que comparar dos tipos de métodos de regulación de la natalidad o un tipo con un método "simulado".

Se encontraron 49 ensayos. Estos ensayos compararon 52 pares diferentes de métodos de regulación de la natalidad, o un método de regulación de la natalidad y un método "simulado". Los cuatro ensayos con un grupo de método simulado o ningún método no mostraron que estas píldoras o parches provoquen cambios en el peso. En su mayoría los estudios de diferentes métodos de regulación de la natalidad no mostraron diferencias grandes en el peso. Además, las mujeres no interrumpieron el uso de la pastilla o el parche debido a cambios en el peso. Las pruebas no fueron suficientemente sólidas para tener la seguridad de que estos métodos no provocaron algún cambio en el peso. Sin embargo, no se encontraron efectos importantes sobre el peso. Para analizar el vínculo entre estos métodos de regulación de la natalidad y el cambio en el peso, los estudios deben tener un grupo de método "simulado" o un grupo que no utilice hormonas. Tener este tipo de grupo control ayudaría a eliminar otros factores como el cambio en el peso con el transcurso del tiempo.

Authors' conclusions

Implications for practice

The four trials with a placebo or no intervention group did not find evidence supporting a causal association between combination contraceptives and weight change. Also, most comparisons of different combination contraceptives showed no substantial difference in weight or difference in discontinuation rates due to weight change. Available evidence is insufficient to determine the effect of combination contraceptives on weight, but no large effect is evident. The medical usefulness of weighing women who use combination contraceptives appears to be limited. Appropriate and accurate counseling about typical weight gain over time may help reduce discontinuation of contraceptives due to perceptions of weight gain.

Implications for research

Randomized controlled trials to evaluate the link between combination contraceptives and weight change require a placebo or non‐hormonal group to control for other factors, including changes in weight over time. In addition, improved reporting of study methods and results would permit the inclusion of more trials and strengthen the interpretation. Trials should also attempt to collect and report weight data for those who discontinue early or are excluded from the trial.

Background

Weight gain is often considered a side effect of using combination contraceptives (that is, an estrogen plus a progestin) (IOM 1996; Nelson 2007), and many women and clinicians believe that an association exists. Almost three‐quarters of women in a random survey conducted in the United Kingdom reported believing that weight gain was related to oral contraceptive use (Turner 1994). In a Canadian survey of women filling an oral contraceptive (OC) prescription (Gaudet 2004), 68% had counseling from their physician on weight gain and the pill. Of those who had counseling, 36% said their weight would stay the same while on the pill compared to 50% of those who had no counseling. In the United States, 45% of adolescents starting OC use believed that oral contraceptive use increased the risk of weight gain (Emans 1987). Also, in a large German convenience sample, about 27% of ever users reported gaining weight from oral contraceptive use (Oddens 1999). In a representative sample of 3600 females in France, aged 15 to 45 years, 1665 were taking OCs (Le 2003). Of these women using the pill, 30% claimed to have gained weight on their most recent pill.

Concern about weight gain can deter the initiation of combination contraceptives and cause early discontinuation among users. Weight gain was the most frequently cited reason for oral contraceptive discontinuation in a national study of adult women in the United States (Rosenberg 1998). A second survey found that about 20% of women claimed that weight gain was a reason for oral contraceptive discontinuation or failure to initiate use (Wysocki 2000). In a convenience sample of oral contraceptive users in five European nations, women who reported weight gain had a relative risk of 1.4 (95% CI 1.2 to 1.6) of method discontinuation before two years of use compared to those who did not report a gain in weight (Rosenberg 1995). Furthermore, even the perception of weight gain can lead to contraceptive discontinuation. A United States study found that women who stopped using OCs were more likely to report weight gain than those who continued using the method, even with no significant difference in measured weight gain between the two groups (Emans 1987). Thus, concern about weight gain limits the use of a highly effective method of contraception.

Nevertheless, a causal relationship between combination contraceptives and weight gain has not been established. Several mechanisms by which combination contraceptives could lead to weight gain have been hypothesized. In general, weight gain is due to an increase in one or more factors of fluid retention, muscle mass, and fat deposition. Fluid retention could be induced by the mineralocorticoid activity that occurs when ethinyl estradiol, the estrogen in combination oral contraceptives, enters the renin‐angiotensin‐aldosterone system (Corvol 1983). Estrogen has been associated with increased subcutaneous fat, especially in the breasts, hips, and thighs (Nelson 2007). The anabolic properties of combination contraceptives could result in increased food intake through a physiological effect on satiety and appetite. Androgens may stimulate nitrogen retention and increase muscle mass, although it is unlikely that oral contraceptives would cause such weight gain (Nelson 2007).

The possible causal association between combination contraceptives and weight gain is difficult to study for several reasons. During adolescence, some weight gain is developmentally normal and appropriate. Also, women tend to gain weight over time (Flegal 2000). A contemporaneous control group is needed, but a randomized controlled trial comparing a combination contraceptive method with a placebo or non‐hormonal method for contraception raises ethical issues. Few such studies have been conducted. Comparing combination contraceptive products is complicated by the variety of formulations and regimens. In addition, most combination contraceptive studies have been of short duration (that is, six cycles or fewer); more time might be required for the weight gain to become evident. Finally, no consensus exists regarding what constitutes excessive weight gain. Ideally, studies would set an a priori definition of clinically important weight gain, but this is rarely specified, perhaps because weight change is not a primary outcome in most comparison trials of combination contraception. Most studies that present a dichotomous classification for weight gain selected either 2.0 or 2.3 kilograms as the cut point; however, the justification for this decision is not apparent. Even if clinically important weight gain was well specified, any gain in weight could still be relevant since the mere perception of weight gain is associated with discontinuation of oral contraception.

Objectives

The aim of the review was to evaluate the potential association between combination contraceptive use and changes in weight. The primary hypothesis was that combination contraceptives do not result in weight changes greater than that of a placebo. The secondary hypothesis was that different formulations and regimens of combination contraceptives are not associated with differences in weight changes.

Methods

Criteria for considering studies for this review

Types of studies

All randomized controlled trials reported in English (Juni 2002; Moher 2000) that compared a combination contraceptive to a placebo, no intervention, or a combination contraceptive that differed in drug, dosage, regimen, or study length.

Types of participants

Women of reproductive age without medical contraindications to combination contraceptives.

Types of interventions

Any combination contraceptive compared to a placebo, no intervention, or another combination contraceptive. Trial drug interventions must have included at least three consecutive cycles to be eligible.

Types of outcome measures

Trials must have collected data on change in body weight to be eligible for inclusion. Weight change could have been measured as either the change in the study group's mean weight or as the proportion of the study group who lost or gained more than a specified amount.

Search methods for identification of studies

Electronic searches

In November 2013, we searched the computerized databases Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, POPLINE, EMBASE, and LILACS for studies of combination contraceptives. We also searched for trials via ClinicalTrials.gov and the search portal of the International Clinical Trials Registry Platform (ICTRP). The strategies are given below.

Searching other resources

For the initial review, we wrote to known investigators and manufacturers to request information about other published or unpublished trials not discovered in our search.

Data collection and analysis

Selection of studies

All titles and abstracts identified during the literature searches were assessed for inclusion, and all potentially relevant articles were photocopied. For the initial review, we wrote to the manufacturers of combination contraception and authors of the included trials to seek other published or unpublished trials.

Data extraction and management

The abstracted data were entered into RevMan and were double‐checked by a second author. The analysis depended on the data available. For the mean change in weight between baseline and post‐treatment measurements, the mean difference (MD) with 95% confidence interval (CI) was calculated using a fixed‐effect model. Alternatively, the Peto odds ratio (OR) with 95% CI was calculated using the proportion of women who gained or lost more than a specified amount of weight.

Significant weight change could be considered a negative side effect of contraceptive use. We used a consistent direction for the graph labels even though the outcomes differed. Therefore, the intervention ‘favors treatment’ if the change is greater in the control group. The intervention ‘favors control’ if the change is greater in the treatment group.

Assessment of risk of bias in included studies

The validity of trials was critically appraised by assessing potential biases; however, summary quality scores were not calculated since the available evidence does not support their use (Higgins 2011). The appraisal of potential biases concentrated on the study design, blinding, randomization method, group allocation concealment, and loss to follow up and early discontinuation.

Measures of treatment effect

Despite some trials reporting weight change data for multiple cycles, only one weight change measure was abstracted for each intervention group. We chose the cycle 12, cycle 6, or last treatment cycle data (in this order of preference) to facilitate comparisons between trials. For trials that included more than two interventions, comparisons were made between the control group and the other groups. If the authors did not identify a control group, all possible combinations were included in the review. We did not use any technique to control for multiple testing.

Significance testing has been criticized for forcing the decision to recognize a difference between two interventions to rest on an arbitrary alpha‐level. Rather than determine differences solely based on a dichotomous classification of the P value, analyses using interval estimation consider both the location of the point estimate and the spread of the CI (Rothman 1998). While this process introduces more subjectivity, borderline 'statistically significant' results are not overlooked and clinically insignificant results are not ascribed undue importance. Although interval estimation is a preferable method, given the reliance on significance testing, we presented results based on both considerations.

Dealing with missing data

For the initial review, we wrote to the authors of 94 trials that either did not report weight data or reported insufficient details. At that point we revised and broadened the search strategy and decided that continuing to contact the authors of trials that appeared to be eligible except for a lack of weight data was no longer feasible. The 14 trials with additional, unpublished data supplied by the authors contacted before the protocol change were included in the present review.

Since point estimates that are not accompanied by a measure of sampling variation have limited interpretation, trial reports that did not include the standard error, standard deviation, or CI for the mean change in weight were not included in the review. For trials that did not report the denominators used to calculate the mean weight difference, or the percentage of women experiencing weight change, we estimated these numbers based on denominators used for other outcomes or the number of women who completed the trial.

Data synthesis

Studies were combined for a meta‐analysis only when identical drugs, dosages, regimens, and delivery systems were compared. No sensitivity analyses were planned since few trials were anticipated to be eligible for meta‐analysis. The data abstracted for the review were dependent on the analytic method used in the trial report (for example, intent to treat, per protocol, or a modification of either type).

Results

Description of studies

Results of the search

Initial review

The initial search strategy in 2002 yielded 570 reports of randomized controlled trials that compared a combination contraceptive to a placebo or to another combination contraceptive. Of those, 476 articles were not eligible for inclusion due to a study length less than three treatment cycles in duration or a lack of reported weight change. An additional 53 articles with weight data were excluded since they lacked an estimate of the sampling variability for the mean difference in weight. The 41 eligible articles, including the 14 articles with additional unpublished data from the authors, reported on 44 trials. One article (Oelkers 2000) described two trials, and two articles (Coney 2001; Kaunitz 2000) each reported pooled results from two eligible trials with similar or identical protocols. Since they could not be disaggregated, we treated the pooled results as if they were from one larger trial, for a total of 42 trials.

Updates

  • 2005: 12 new RCTs of combination contraceptives also included a weight measurement. Only two trials were of sufficient duration and had reported weight change data with sampling variability, which yielded 44 trials.

  • 2008: 13 trials had weight measurements, but only three had sufficient data for inclusion, for a new total of 47 trials.

  • 2011: Of five possible trials, two met our inclusion criteria. The new total was 49 trials.

  • 2013: The search yielded 134 unduplicated citations from the electronic databases. We reviewed the full text of eight articles; none met our inclusion criteria. In addition, we found 32 unduplicated listings in ClinicalTrials.gov and ICTRP. We identified one ongoing trial that was relevant (Mahidol 2013).

Included studies

Of the 49 eligible trials, four included a placebo group or no hormonal method. Three of these trials evaluated oral contraceptives (Coney 2001; Goldzieher 1971; Procter‐Gray 2008) and one studied a contraceptive skin patch (Sibai 2001). The products evaluated in the 49 trials included 18 progestins and three estrogens. Trials examined combination oral contraceptives except for the following comparisons: two combination injectables (Sang 1995); two combination vaginal rings (Weisberg 1999); a combination skin patch (Sibai 2001; Stewart 2005); and a combination ring with an oral contraceptive (Milsom 2006; Oddsson 2005). Seven trials included more than two intervention groups; three of these trials did not specify a control group.

The sample sizes for the trials ranged from 20 to 5654 randomized participants with a median of 196 participants. The study location was not described for 13 trials; the other studies were conducted in locations worldwide. The number of trial sites ranged from a single site (12 trials) to 131 sites, except for 10 trials that did not specify the number of sites. The duration of the trials ranged from 3 to 24 treatment cycles with most trials designed to be either 6 or 12 treatment cycles in length. The eligibility criteria for the participants varied among the trials with most trials recruiting healthy women of reproductive age without contraindications to hormonal contraceptive use. However, six of the articles did not describe any inclusion or exclusion criteria.

Risk of bias in included studies

The quality of the reporting of the trials on this topic was generally poor, and poor quality is associated with empirical evidence of bias (Schulz 1995).

Allocation

The method of generating the randomization sequence was not reported for 31 trials. The remaining 18 trials included at least some detail of the process (for example, use of a random numbers table, pre‐distributed lists, or computer‐generated sequence). Most trial reports (N = 45) did not describe a method of allocation concealment (Schulz 2002a). Cachrimanidou 1993 and Kashanian 2010 reported the use of sealed envelopes but did not provide details on whether the envelopes were impervious to deciphering (for example, use of opaque, sequentially‐numbered envelopes). Only three articles reported adequate allocation concealment: Miller 2001 used sealed, sequentially‐numbered, opaque envelopes containing carbon paper, which allowed the participant to sign the allocation card before study staff opened the envelope and learned the group assignment; Milsom 2006 and Oddsson 2005 had interactive voice response systems for the randomization process.

Only four articles reported the number of women recruited for the trial (Cachrimanidou 1993; Kashanian 2010; Oddsson 2005; Wiegratz 2002). One article stated that not all randomized women were included in the study results but did not specify the number of randomized women (Worsley 1980). A second trial report included sample sizes for the weight outcome but did not state whether these data included all randomized women (Sibai 2001). Although they reported the total number of randomized women, seven trial reports did not provide the number of randomized women stratified by study group.

Blinding

About half of the eligible trials were open; two were single‐blinded, 10 were double‐blinded, and one was triple‐blinded. Blinding was not mentioned in 15 trials. Participants, investigators, and outcome assessors were blinded as to group assignment in the triple‐blinded study (Oelkers 1995), and participants appeared to have been blinded in two of the double‐blinded trials (Coney 2001; Goldzieher 1971) using active and placebo pills that were identical in appearance. Since the Goldzieher 1971 trial reported that the randomization code was not broken during the study, the blinding of the investigators can be inferred. Two trials did not inform the assessors of group assignment, but the investigators and participants were not blinded (Kashanian 2010; Procter‐Gray 2008). The remaining blinded trials were unclear about who was blinded, and none of the trials included details regarding whether blinding appeared to have been implemented successfully (Schulz 2002b).

Incomplete outcome data

Eleven trials did not report the denominators used to derive the mean weight difference (Coenen 1996) or the percentage of women with weight change greater than a specified amount (Brill 1991; Dionne 1974; Endrikat 1999; Endrikat 2001a; Goldzieher 1971; Halbe 1998; Koetsawang 1995; Lachnit‐Fixson 1984; Oelkers 1995; Rosenbaum 2000). Discrepancies existed in at least 13 trials, since more women were missing in the weight estimate than could be explained with the possible reasons in the article (for example, non‐starters, early discontinuation, those lost to follow up, or exclusion).

Deducing which participants were included in the reported weight change estimate was hindered for most trials due to the lack of details regarding the method of analysis. An intention‐to‐treat analysis was described for three trials (Oddsson 2005; Procter‐Gray 2008; Wiegratz 2002); a per‐protocol analysis (also called valid‐case) was reported for three trials (Endrikat 1999; Serfaty 1998; Winkler 1996); and an analysis based on all participants who started treatment was reported for five trials (Coney 2001; Endrikat 2001b; Gruber 2006; Kaunitz 2000; Milsom 2006). Two trials (Endrikat 2001a; Stewart 2005) described intention‐to‐treat or valid‐case analyses but did not specify which was used for the weight change data. Two trials (Spellacy 1970; Van der Does 1995) had complete study participation and based the weight estimates on measurements from all participants. Kashanian 2010 excluded from the analysis two women who discontinued the intervention. The remaining 33 trials did not specify the analytic method used for the weight change data.

Other potential sources of bias

Change in body weight was a primary outcome for only one trial (Sibai 2001). Most trials either recorded weight at the baseline and follow‐up clinic visits or did not describe the method used for measuring weight. Liukko 1987 reported that the clinic visits, in which weight was measured, were scheduled around day 22 of the cycle. Milsom 2006 and Procter‐Gray 2008 described the methods used to standardize weight measurements. Four trials instructed participants to weigh and record their weight at home (Rosenbaum 2000), at home without clothing every second day (Oelkers 2000, Study 2) and in a fasting state (Oelkers 1995), or at home without clothing on a weekly basis (Oelkers 2000, Study 3).

Most trial reports either did not include data on loss to follow up (19 trials) or reported it combined with early discontinuation (nine trials). Loss to follow up ranged from zero to 17% for the 20 trials with loss to follow up reported separately from early discontinuation and from 10% to 35% for those that only reported losses from all causes. Early discontinuation ranged from zero to 39% for the 31 trials that reported this study factor separately. Eight trial reports did not include information on early discontinuation. Furthermore, 18 trial reports described excluding randomized women from study participation or analysis. Exclusions after randomization are not consistent with an intention‐to‐treat analysis and could have led to biased results (Weiss 1998).

Effects of interventions

The trials included 85 weight change comparisons for 52 distinct contraceptive pairs (or a placebo) that were eligible for the present review. We combined data from two or more trials for four of the 84 comparisons since they were identical in drug, dosage, regimen, and study length. The comparisons of a combination contraceptive with a placebo or no hormonal method showed no significant differences in weight change. These included five comparisons between an oral contraceptive and placebo (Coney 2001; Goldzieher 1971) or no intervention (Procter‐Gray 2008) and one comparison between a combination skin patch and placebo (Sibai 2001).

The study groups differed significantly in six comparisons of two pills and one comparison of the vaginal ring with an OC.

  • Three studies showed differences in the numbers of women with a weight change of more than 2 kg.

    • For gaining more than 2 kg, the OR was 3.29 (95% CI 1.84 to 5.88) for women assigned to oral desogestrel 150 μg and ethinyl estradiol (EE) 30 μg compared to those with oral levonorgestrel 50‐75‐125 μg and EE 30‐40‐30 μg (Lachnit‐Fixson 1984) (Analysis 11.1).

    • For losing more than 2 kg, the OR was 9.22 (95% CI 1.79 to 55.04) for oral drospirenone 3 mg and EE 15 μg compared to oral levonorgestrel 150 μg and EE 30 μg (Oelkers 1995) (Analysis 20.2).

    • The OR for losing more than 2 kg was 1.65 (95% CI 1.13 to 2.41) for the oral desogestrel 150 μg and EE 20 μg group compared to the oral gestodene 75 μg and EE 20 μg group (Serfaty 1998) (Analysis 9.2).

  • Four studies showed differences in the mean weight change between groups. One group had a slight increase while the other group showed a small decrease or no change.

    • The mean difference in Kaunitz 2000 was 0.26 kg (95% CI 0.12 to 0.40) (Analysis 46.1). Women assigned to oral norethindrone 500‐750‐1000 μg and EE 35 μg group had a slight mean increase, and those in the oral desogestrel 100‐125‐150 μg and EE 25 μg group had a slight decrease.

    • In Loudon 1990, the mean difference was 0.70 kg (95% CI 0.14 to 1.26) (Analysis 35.1). The group with oral levonorgestrel 150 μg and EE 30 μg gained, on average, while those with oral gestodene 75 μg and EE 30 μg lost a little weight.

    • The mean difference was ‐0.67 kg (95% CI ‐1.16 to ‐0.18) in Gruber 2006 (Analysis 23.1). On average, the women assigned to drospirenone 3 mg and EE 20 μg had a slight decrease, and the group with desogestrel 150 μg and EE 20 μg had a small increase.

    • Tn Milsom 2006, the mean difference was 0.40 kg (95% CI 0.03 to 0.77) (Analysis 52.1). Women assigned to the vaginal ring gained on average while the group with the combination oral contraceptive (COC) containing drospirenone 3 mg and EE 30 µg had no change overall.

Six additional comparisons had a point estimate and 95% CI that were consistent with at least a minimal difference between the two groups. Odds ratios for three of the six studies were as follows:

  • OR 1.54 (95% CI 0.92 to 2.60) for gaining more than 2 kg with oral gestodene 75 μg and EE 30 μg versus oral norgestimate 250 μg and EE 35 μg (Brill 1991) (Analysis 29.1);

  • OR 1.75 (95% CI 0.98 to 3.11) for gaining more than 2.5 kg with oral lynestrenol 2 mg and EE 40 μg versus oral lynestrenol 1 mg and EE 40 μg (Koetsawang 1977) (Analysis 42.1);

  • OR 1.69 (95% CI 0.89 to 3.20) of losing more than 2 kg with oral norethisterone 500 μg and EE 20 μg versus oral levonorgestrel 150 μg and EE 30 μg (Endrikat 2001b) (Analysis 45.2).

Mean differences in kg were as follows for the other three studies:

  • MD 1.30 (95% CI ‐0.32 to 2.92) between oral levonorgestrel 50, 75, 125 μg and EE 30, 40, 30 μg group and oral desogestrel 50‐100‐150 μg and EE 35‐30‐30 μg group (Van der Does 1995) (Analysis 38.2);

  • MD 1.80 (95% CI ‐0.73 to 4.33) between a standard versus prolonged oral norgestrel and EE regimen (Miller 2001) (Analysis 48.1);

  • MD 1.14 (95% CI ‐0.54 to 2.82) between oral dl‐norgestrel 500 μg and EE 50 μg group and oral norethisterone acetate 1 mg and EE 50 μg group (Worsley 1980) (Analysis 18.1).

Twenty‐one trial reports provided quantitative data on the primary reasons for early discontinuation. Ten of these trial reports included weight change as a distinct category for early discontinuation from trial participation (Table 1). The proportions of women who discontinued due to weight changes were small (zero to 5%) and did not differ between the study groups. Sang 1995 included the mean weight gain for the women who cited weight gain as the primary or secondary reason for early discontinuation. In the group with injectable medroxyprogesterone acetate 25 mg and estradiol cypionate 5 mg, the 18 women who attributed weight gain to the contraceptive had a mean gain of 2.8 kg compared to 3.1 kg for the 16 women in the group assigned to the injectable norethisterone enanthate 50 mg and estradiol valerate 5 mg (Sang 1995).

Open in table viewer
Table 1. Discontinuation due to weight change

Study ID

Intervention group

n

N (randomized women)

Cachrimanidou 1993

Prolonged desogestrel / ethinyl estradiol (EE) regimen

10

200

Standard desogestrel / EE regimen

1

100

Coenen 1996

Norgestimate 250 μg / EE 35 μg

1

25

Gestodene 75 μg / EE 30 μg

0

25

Desogestrel 150 μg / EE 30 μg

0

25

Desogestrel 150 μg / EE 20 μg

0

25

Coney 2001

Levonorgestrel 100 μg / EE 20 μg

2

359

Placebo

0

362

Dionne 1974

Levonorgestrel 250 μg / EE 50 μg

3

73

Levonorgestrel 150 μg / EE 30 μg

1

77

Halbe 1998

Gestodene 75 μg / EE 30 μg

4

279

Desogestrel 150 μg / EE 30 μg

0

316

Kirkman 1994

Gestodene 75 μg / EE 30 μg

4

505

Desogestrel 150 μg / EE 20 μg

2

501

Miller 2001

Standard norgestrel / EE regimen

0

44

Prolonged norgestrel / EE regimen

1

46

Oddsson 2005

Vaginal ring etonogestrel 120 µg / EE 15 µg

2

512

Levonorgestrel 150 µg / EE 30 µg

6

518

Sang 1995

Injectable medroxyprogesterone acetate 25 mg / estradiol cypionatge (EC) 5 mg

14

1955

Injectable norethisterone enanthate 50 mg / estradiol valerate (EV) 5 mg

10

1960

Wiik 1993

Norethisterone 500‐1000 μg / EE 35 μg

3

100

Levonorgestrel 50‐75‐125 μg / EE 30‐40 μg

1

96

Discussion

Summary of main results

The four trials that included a placebo group or 'no intervention' group (Coney 2001; Goldzieher 1971; Procter‐Gray 2008; Sibai 2001) did not find evidence supporting the putative association between combination contraceptive use and weight change. The lack of an association in those trials could be due to the limited number of contraceptives evaluated. Goldzieher 1971, conducted more than three decades ago, studied three high‐estrogen dose oral contraceptives. Coney 2001 and Procter‐Gray 2008 evaluated one oral contraceptive each. Sibai 2001 studied one skin patch. Given the numerous combination contraceptive drugs, doses, and regimens, the possibility that one or more combination contraceptives could cause weight change cannot be eliminated with the data from the four placebo‐controlled randomized trials conducted to date.

Of the 79 weight change comparisons evaluating two combination contraceptives, seven showed a difference in the mean weight change or the proportion of women gaining or losing more than a set amount of weight. Even if no association existed between combination contraceptives and weight, one would expect several significant results (Type I errors) since numerous comparisons were made. Regardless of statistical significance, the clinical significance seems negligible. The point estimates for the mean difference in weight between the comparison groups were small. The largest notable difference was 1.80 kg (95% CI ‐0.73 to 4.33) after 12 treatment cycles (Miller 2001). The ORs for the proportions of women who gained or lost more than a set amount were generally either weak or too imprecise to convey much meaning. The CI from Oelkers 1995 was very wide since no one in the levonorgestrel and EE group lost more than the specified 2 kg.

If a mechanism for weight gain were estrogen‐dependent, two contraceptives containing the same progestin and estrogen types but different hormone doses might show more weight gain with the higher‐estrogen contraceptive. In this review, 11 of the 51 comparison pairs included two oral contraceptives with identical progestin and estrogen types but different hormone doses or regimens. Only Miller 2001 detected a possible difference in weight change between the groups, and the higher weight gain was for the group assigned less estrogen. While a dose‐related effect would have supported the hypothesized causal link between estrogen and weight gain, the lack of this finding does not disprove the possible association. The studies could have been underpowered to detect a dose‐gradient response between the estrogen content and weight gain.

Overall completeness and applicability of evidence

Only one trial examined weight change as a primary outcome, so most trials did not use rigorous methods for measuring weight. The reliability of the measurements could be affected by numerous factors, such as the use of calibrated scales, the time of day and cycle when measurements were collected, the use of a fasting state, and the amount of clothing on the participant. The degree of error in measuring weight change is likely to be similar between study groups and to dilute the effect estimate toward the null value of no difference.

The trials also could have failed to detect differences in weight if the rates for early discontinuation or loss to follow up had systematically differed between intervention groups for women who gained or lost weight. Ten trials reported the proportion of women for whom weight change was the primary reason for early discontinuation, and did not find differences by study group. Also, the one trial that reported the mean weight gain for the women who discontinued early for this reason found similar mean weight changes for the two combination injectable groups. The interpretation of the trial results would have been strengthened by including weight change data for women who did not complete the trial.

Quality of the evidence

More than 25% of the trials had high risk of bias due to lack of blinding or incomplete outcome data (Figure 1). The majority of studies had unclear risk of bias due to missing information on randomization sequence generation or allocation concealment. However, most of those trials were published before CONSORT (Moher 2001; CONSORT 2009) (Figure 2).


Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.


Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).
Figuras y tablas -
Analysis 1.1

Comparison 1 Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).

Comparison 2 Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).
Figuras y tablas -
Analysis 2.1

Comparison 2 Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).

Comparison 3 Levonorgestrel 100 µg and EE 20 µg versus placebo, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 3.1

Comparison 3 Levonorgestrel 100 µg and EE 20 µg versus placebo, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 4 Norgestrel 300 µg and EE 30 µg versus no intervention, Outcome 1 Mean weight change in kg per year.
Figuras y tablas -
Analysis 4.1

Comparison 4 Norgestrel 300 µg and EE 30 µg versus no intervention, Outcome 1 Mean weight change in kg per year.

Comparison 5 Norethindrone 1 mg and mestranol 50 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).
Figuras y tablas -
Analysis 5.1

Comparison 5 Norethindrone 1 mg and mestranol 50 µg versus placebo, Outcome 1 Gained >2.3 kg (cycle 4).

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 1 Gained >5% baseline weight (cycle 9).
Figuras y tablas -
Analysis 6.1

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 1 Gained >5% baseline weight (cycle 9).

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 2 Lost >5% baseline weight (cycle 9).
Figuras y tablas -
Analysis 6.2

Comparison 6 Skin patch norelgestromin 150 µg and EE 20 µg versus placebo, Outcome 2 Lost >5% baseline weight (cycle 9).

Comparison 7 Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen, Outcome 1 Mean weight change (112 days or cycle 4).
Figuras y tablas -
Analysis 7.1

Comparison 7 Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen, Outcome 1 Mean weight change (112 days or cycle 4).

Comparison 8 Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 8.1

Comparison 8 Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean body mass percentage change (cycle 6).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 9.1

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 9.2

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 3 Gained >2 kg (cycle 12).
Figuras y tablas -
Analysis 9.3

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 3 Gained >2 kg (cycle 12).

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 4 Lost >2 kg (cycle 12).
Figuras y tablas -
Analysis 9.4

Comparison 9 Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg, Outcome 4 Lost >2 kg (cycle 12).

Comparison 10 Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 10.1

Comparison 10 Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean body mass percentage change (cycle 6).

Comparison 11 Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 11.1

Comparison 11 Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 12 Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen, Outcome 1 Gained >2 kg (cycle 7).
Figuras y tablas -
Analysis 12.1

Comparison 12 Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen, Outcome 1 Gained >2 kg (cycle 7).

Comparison 13 Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 13.1

Comparison 13 Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 14.1

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 14.2

Comparison 14 Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 15.1

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 15.2

Comparison 15 Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 16.1

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 1 Gained >5% baseline weight (cycle 3).

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).
Figuras y tablas -
Analysis 16.2

Comparison 16 Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg, Outcome 2 Lost >5% baseline weight (cycle 3).

Comparison 17 Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 17.1

Comparison 17 Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 18 Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 18.1

Comparison 18 Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 3).
Figuras y tablas -
Analysis 19.1

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 3).

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 3).
Figuras y tablas -
Analysis 19.2

Comparison 19 Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 3).

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 20.1

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 20.2

Comparison 20 Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 21.1

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 21.2

Comparison 21 Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 13).
Figuras y tablas -
Analysis 22.1

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 13).

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 13).
Figuras y tablas -
Analysis 22.2

Comparison 22 Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 13).

Comparison 23 Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg, Outcome 1 Mean weight change in kg (cycle 7).
Figuras y tablas -
Analysis 23.1

Comparison 23 Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg, Outcome 1 Mean weight change in kg (cycle 7).

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 24.1

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 24.2

Comparison 24 Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 25 Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 25.1

Comparison 25 Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 26.1

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 26.2

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 3 Gained >2 kg (cycle 12).
Figuras y tablas -
Analysis 26.3

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 3 Gained >2 kg (cycle 12).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 4 Lost >2 kg (cycle 12).
Figuras y tablas -
Analysis 26.4

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 4 Lost >2 kg (cycle 12).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 5 Gained >2 kg (cycle 13).
Figuras y tablas -
Analysis 26.5

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 5 Gained >2 kg (cycle 13).

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 6 Lost >2 kg (cycle 13).
Figuras y tablas -
Analysis 26.6

Comparison 26 Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg, Outcome 6 Lost >2 kg (cycle 13).

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 27.1

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean body mass percentage change (cycle 6).

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 2 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 27.2

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 2 Mean weight change in kg (cycle 6).

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 3 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 27.3

Comparison 27 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 3 Mean weight change in kg (cycle 12).

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 28.1

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg ( cycle 6).
Figuras y tablas -
Analysis 28.2

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg ( cycle 6).

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 3 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 28.3

Comparison 28 Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 3 Mean body mass percentage change (cycle 6).

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 29.1

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 2 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 29.2

Comparison 29 Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 2 Mean body mass percentage change (cycle 6).

Comparison 30 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 30.1

Comparison 30 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 31 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 31.1

Comparison 31 Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 32 Prolonged gestodene and EE regimen versus standard gestodene and EE regimen, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 32.1

Comparison 32 Prolonged gestodene and EE regimen versus standard gestodene and EE regimen, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 33.1

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 33.2

Comparison 33 Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.5 kg (cycle 24).
Figuras y tablas -
Analysis 34.1

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.5 kg (cycle 24).

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2.5 kg (cycle 24).
Figuras y tablas -
Analysis 34.2

Comparison 34 Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Lost >2.5 kg (cycle 24).

Comparison 35 Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 35.1

Comparison 35 Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 36 Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.7 kg (cycle 6).
Figuras y tablas -
Analysis 36.1

Comparison 36 Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2.7 kg (cycle 6).

Comparison 37 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 37.1

Comparison 37 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 1 Mean BMI change (cycle 6).
Figuras y tablas -
Analysis 38.1

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 1 Mean BMI change (cycle 6).

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 2 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 38.2

Comparison 38 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg, Outcome 2 Mean weight change in kg (cycle 6).

Comparison 39 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 39.1

Comparison 39 Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 40 Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 40.1

Comparison 40 Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 41 Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen, Outcome 1 Mean weight change in kg (cycle 3).
Figuras y tablas -
Analysis 41.1

Comparison 41 Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen, Outcome 1 Mean weight change in kg (cycle 3).

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 1 Gained >2.5 kg (cycle 12).
Figuras y tablas -
Analysis 42.1

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 1 Gained >2.5 kg (cycle 12).

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 2 Lost >2.5 kg (cycle 12).
Figuras y tablas -
Analysis 42.2

Comparison 42 Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg, Outcome 2 Lost >2.5 kg (cycle 12).

Comparison 43 Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 43.1

Comparison 43 Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 44.1

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Mean body mass percentage change (cycle 6).
Figuras y tablas -
Analysis 44.2

Comparison 44 Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg, Outcome 2 Mean body mass percentage change (cycle 6).

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).
Figuras y tablas -
Analysis 45.1

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gained >2 kg (cycle 6).

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).
Figuras y tablas -
Analysis 45.2

Comparison 45 Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >2 kg (cycle 6).

Comparison 46 Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg, Outcome 1 Mean weight change in kg (cycle 6).
Figuras y tablas -
Analysis 46.1

Comparison 46 Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg, Outcome 1 Mean weight change in kg (cycle 6).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Weight gain >=5% (cycle 6).
Figuras y tablas -
Analysis 47.1

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Weight gain >=5% (cycle 6).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Weight gain >=5% (cycle 13).
Figuras y tablas -
Analysis 47.2

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Weight gain >=5% (cycle 13).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 3 Weight loss >=5% (cycle 6).
Figuras y tablas -
Analysis 47.3

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 3 Weight loss >=5% (cycle 6).

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 4 Weight loss >=5% (cycle 13).
Figuras y tablas -
Analysis 47.4

Comparison 47 Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 4 Weight loss >=5% (cycle 13).

Comparison 48 Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 48.1

Comparison 48 Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 49 Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg, Outcome 1 Mean weight change in kg (cycle 12).
Figuras y tablas -
Analysis 49.1

Comparison 49 Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg, Outcome 1 Mean weight change in kg (cycle 12).

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Gain >2 kg (cycle 4).
Figuras y tablas -
Analysis 50.1

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 1 Gain >2 kg (cycle 4).

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 4).
Figuras y tablas -
Analysis 50.2

Comparison 50 Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg, Outcome 2 Lost >2 kg (cycle 4).

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gain >=7% body weight (cycle 13).
Figuras y tablas -
Analysis 51.1

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 1 Gain >=7% body weight (cycle 13).

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >=7% body weight (cycle 13).
Figuras y tablas -
Analysis 51.2

Comparison 51 Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg, Outcome 2 Lost >=7% body weight (cycle 13).

Comparison 52 Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 13 or last assessment).
Figuras y tablas -
Analysis 52.1

Comparison 52 Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg, Outcome 1 Mean weight change in kg (cycle 13 or last assessment).

Table 1. Discontinuation due to weight change

Study ID

Intervention group

n

N (randomized women)

Cachrimanidou 1993

Prolonged desogestrel / ethinyl estradiol (EE) regimen

10

200

Standard desogestrel / EE regimen

1

100

Coenen 1996

Norgestimate 250 μg / EE 35 μg

1

25

Gestodene 75 μg / EE 30 μg

0

25

Desogestrel 150 μg / EE 30 μg

0

25

Desogestrel 150 μg / EE 20 μg

0

25

Coney 2001

Levonorgestrel 100 μg / EE 20 μg

2

359

Placebo

0

362

Dionne 1974

Levonorgestrel 250 μg / EE 50 μg

3

73

Levonorgestrel 150 μg / EE 30 μg

1

77

Halbe 1998

Gestodene 75 μg / EE 30 μg

4

279

Desogestrel 150 μg / EE 30 μg

0

316

Kirkman 1994

Gestodene 75 μg / EE 30 μg

4

505

Desogestrel 150 μg / EE 20 μg

2

501

Miller 2001

Standard norgestrel / EE regimen

0

44

Prolonged norgestrel / EE regimen

1

46

Oddsson 2005

Vaginal ring etonogestrel 120 µg / EE 15 µg

2

512

Levonorgestrel 150 µg / EE 30 µg

6

518

Sang 1995

Injectable medroxyprogesterone acetate 25 mg / estradiol cypionatge (EC) 5 mg

14

1955

Injectable norethisterone enanthate 50 mg / estradiol valerate (EV) 5 mg

10

1960

Wiik 1993

Norethisterone 500‐1000 μg / EE 35 μg

3

100

Levonorgestrel 50‐75‐125 μg / EE 30‐40 μg

1

96

Figuras y tablas -
Table 1. Discontinuation due to weight change
Comparison 1. Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.3 kg (cycle 4) Show forest plot

1

113

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.02 [0.46, 2.26]

Figuras y tablas -
Comparison 1. Dimethisterone 25 mg and ethinyl estradiol (EE) 100 µg versus placebo
Comparison 2. Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.3 kg (cycle 4) Show forest plot

1

112

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.57 [0.24, 1.33]

Figuras y tablas -
Comparison 2. Ethynodiol diacetate 1 mg and mestranol 100 µg versus placebo
Comparison 3. Levonorgestrel 100 µg and EE 20 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

473

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐0.23, 0.83]

Figuras y tablas -
Comparison 3. Levonorgestrel 100 µg and EE 20 µg versus placebo
Comparison 4. Norgestrel 300 µg and EE 30 µg versus no intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg per year Show forest plot

1

150

Mean Difference (IV, Fixed, 95% CI)

‐0.54 [‐1.39, 0.31]

Figuras y tablas -
Comparison 4. Norgestrel 300 µg and EE 30 µg versus no intervention
Comparison 5. Norethindrone 1 mg and mestranol 50 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.3 kg (cycle 4) Show forest plot

1

123

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.50 [0.22, 1.17]

Figuras y tablas -
Comparison 5. Norethindrone 1 mg and mestranol 50 µg versus placebo
Comparison 6. Skin patch norelgestromin 150 µg and EE 20 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 9) Show forest plot

1

136

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.95 [0.30, 2.98]

2 Lost >5% baseline weight (cycle 9) Show forest plot

1

136

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.27 [0.04, 1.82]

Figuras y tablas -
Comparison 6. Skin patch norelgestromin 150 µg and EE 20 µg versus placebo
Comparison 7. Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change (112 days or cycle 4) Show forest plot

1

191

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.79, 0.55]

Figuras y tablas -
Comparison 7. Skin patch norelgestromin 150 µg and EE 20 µg: extended versus cyclic regimen
Comparison 8. Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean body mass percentage change (cycle 6) Show forest plot

1

45

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐1.54, 1.74]

Figuras y tablas -
Comparison 8. Desogestrel 150 µg and EE 20 µg versus desogestrel 150 µg and EE 30 µg
Comparison 9. Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

801

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.84 [0.58, 1.22]

2 Lost >2 kg (cycle 6) Show forest plot

1

801

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.65 [1.13, 2.41]

3 Gained >2 kg (cycle 12) Show forest plot

1

1476

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.13 [0.85, 1.49]

4 Lost >2 kg (cycle 12) Show forest plot

1

1476

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.95 [0.68, 1.33]

Figuras y tablas -
Comparison 9. Desogestrel 150 µg and EE 20 µg versus gestodene 75 µg and EE 20 µg
Comparison 10. Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean body mass percentage change (cycle 6) Show forest plot

1

42

Mean Difference (IV, Fixed, 95% CI)

0.60 [‐1.45, 2.65]

Figuras y tablas -
Comparison 10. Desogestrel 150 µg and EE 20 µg versus norgestimate 250 µg and EE 35 µg
Comparison 11. Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

469

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.29 [1.84, 5.88]

Figuras y tablas -
Comparison 11. Desogestrel 150 µg and EE 30 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg
Comparison 12. Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 7) Show forest plot

1

890

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.20 [0.86, 1.68]

Figuras y tablas -
Comparison 12. Standard desogestrel and EE regimen versus prolonged gestodene and EE regimen
Comparison 13. Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

196

Mean Difference (IV, Fixed, 95% CI)

0.57 [‐0.42, 1.56]

Figuras y tablas -
Comparison 13. Prolonged desogestrel and EE regimen versus standard desogestrel and EE regimen
Comparison 14. Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.20 [0.32, 4.51]

2 Lost >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.10 [0.14, 358.08]

Figuras y tablas -
Comparison 14. Dienogest 2 mg, EE 10 µg and estradiol valerate 2 mg versus levonorgestrel 100 µg and EE 20 µg
Comparison 15. Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.95 [0.24, 3.76]

2 Lost >5% baseline weight (cycle 3) Show forest plot

1

49

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.40 [0.45, 121.93]

Figuras y tablas -
Comparison 15. Dienogest 2 mg and EE 20 µg versus levonorgestrel 100 µg and EE 20 µg
Comparison 16. Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >5% baseline weight (cycle 3) Show forest plot

1

48

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.77 [0.18, 3.21]

2 Lost >5% baseline weight (cycle 3) Show forest plot

1

48

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.15, 372.38]

Figuras y tablas -
Comparison 16. Dienogest 2 mg and EE 30 µg versus levonorgestrel 100 µg and EE 20 µg
Comparison 17. Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

21

Mean Difference (IV, Fixed, 95% CI)

0.22 [‐1.30, 1.74]

Figuras y tablas -
Comparison 17. Dl‐norgestrel 500 µg and EE 50 µg versus levonorgestrel 250 µg and EE 50 µg
Comparison 18. Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

16

Mean Difference (IV, Fixed, 95% CI)

1.14 [‐0.54, 2.82]

Figuras y tablas -
Comparison 18. Dl‐norgestrel 500 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg
Comparison 19. Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 3) Show forest plot

2

112

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.00, 6.82]

2 Lost >2 kg (cycle 3) Show forest plot

1

66

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.99 [0.20, 19.82]

Figuras y tablas -
Comparison 19. Drospirenone 2 mg and EE 30 µg versus drospirenone 3 mg and EE 30 µg
Comparison 20. Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.50 [0.05, 5.06]

2 Lost >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.92 [1.79, 55.04]

Figuras y tablas -
Comparison 20. Drospirenone 3 mg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 21. Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.13 [0.01, 2.13]

2 Lost >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.15, 372.38]

Figuras y tablas -
Comparison 21. Drospirenone 3 mg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 22. Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 13) Show forest plot

1

56

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.86 [0.29, 2.56]

2 Lost >2 kg (cycle 13) Show forest plot

1

56

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.38 [0.29, 6.62]

Figuras y tablas -
Comparison 22. Drospirenone 3 mg and EE 30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 23. Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 7) Show forest plot

1

441

Mean Difference (IV, Fixed, 95% CI)

‐0.67 [‐1.16, ‐0.18]

Figuras y tablas -
Comparison 23. Drospirenone 3 mg and EE 20 μg versus desogestrel 150 μg and EE 20 μg
Comparison 24. Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.13 [0.01, 2.13]

2 Lost >2 kg (cycle 6) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.15, 372.38]

Figuras y tablas -
Comparison 24. Drospirenone 3 mg and EE 30 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 25. Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐1.43, 2.03]

Figuras y tablas -
Comparison 25. Ethynodiol diacetate 1 mg and mestranol 100 µg versus chlormadinone acetate 1.5 mg and mestranol 100 µg
Comparison 26. Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

39

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.05 [0.06, 17.51]

2 Lost >2 kg (cycle 6) Show forest plot

1

39

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.79 [0.15, 393.02]

3 Gained >2 kg (cycle 12) Show forest plot

1

452

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.06 [0.63, 1.81]

4 Lost >2 kg (cycle 12) Show forest plot

1

452

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.13 [0.63, 2.03]

5 Gained >2 kg (cycle 13) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.71 [0.14, 3.57]

6 Lost >2 kg (cycle 13) Show forest plot

1

40

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.00, 6.82]

Figuras y tablas -
Comparison 26. Gestodene 75 µg and EE 20 µg versus gestodene 75 µg and EE 30 µg
Comparison 27. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean body mass percentage change (cycle 6) Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

0.7 [‐1.32, 2.72]

2 Mean weight change in kg (cycle 6) Show forest plot

1

805

Mean Difference (IV, Fixed, 95% CI)

0.20 [0.00, 0.40]

3 Mean weight change in kg (cycle 12) Show forest plot

2

462

Mean Difference (IV, Fixed, 95% CI)

0.01 [‐0.50, 0.51]

Figuras y tablas -
Comparison 27. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 20 µg
Comparison 28. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

3

1524

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.18 [0.87, 1.60]

2 Lost >2 kg ( cycle 6) Show forest plot

2

1172

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.34 [0.90, 2.00]

3 Mean body mass percentage change (cycle 6) Show forest plot

1

46

Mean Difference (IV, Fixed, 95% CI)

0.8 [‐1.18, 2.78]

Figuras y tablas -
Comparison 28. Gestodene 75 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 29. Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

357

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.54 [0.92, 2.60]

2 Mean body mass percentage change (cycle 6) Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

1.3 [‐1.03, 3.63]

Figuras y tablas -
Comparison 29. Gestodene 75 µg and EE 30 µg versus norgestimate 250 µg and EE 35 µg
Comparison 30. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

30

Mean Difference (IV, Fixed, 95% CI)

1.25 [‐1.22, 3.72]

Figuras y tablas -
Comparison 30. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 31. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

47

Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐1.09, 0.59]

Figuras y tablas -
Comparison 31. Gestodene 50‐70‐100 µg and EE 30‐40‐30 µg versus norgestimate 250 µg and EE 35 µg
Comparison 32. Prolonged gestodene and EE regimen versus standard gestodene and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

58

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐1.23, 1.23]

Figuras y tablas -
Comparison 32. Prolonged gestodene and EE regimen versus standard gestodene and EE regimen
Comparison 33. Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

418

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.26 [0.74, 2.15]

2 Lost >2 kg (cycle 6) Show forest plot

1

418

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.70, 2.44]

Figuras y tablas -
Comparison 33. Levonorgestrel 100 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 34. Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.5 kg (cycle 24) Show forest plot

1

17

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.66 [0.77, 97.74]

2 Lost >2.5 kg (cycle 24) Show forest plot

1

17

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.88 [0.17, 21.18]

Figuras y tablas -
Comparison 34. Levonorgestrel 150 µg and EE 30 µg versus desogestrel 150 µg and EE 30 µg
Comparison 35. Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

369

Mean Difference (IV, Fixed, 95% CI)

0.7 [0.14, 1.26]

Figuras y tablas -
Comparison 35. Levonorgestrel 150 µg and EE 30 µg versus gestodene 75 µg and EE 30 µg
Comparison 36. Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.7 kg (cycle 6) Show forest plot

1

109

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.92 [0.74, 4.96]

Figuras y tablas -
Comparison 36. Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 37. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

314

Mean Difference (IV, Fixed, 95% CI)

‐0.02 [‐0.06, 0.03]

Figuras y tablas -
Comparison 37. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 38. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean BMI change (cycle 6) Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

0.35 [‐0.13, 0.83]

2 Mean weight change in kg (cycle 6) Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

1.30 [‐0.32, 2.92]

Figuras y tablas -
Comparison 38. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg
Comparison 39. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

33

Mean Difference (IV, Fixed, 95% CI)

0.78 [‐0.28, 1.84]

Figuras y tablas -
Comparison 39. Levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg versus desogestrel 150 µg and EE 20 µg
Comparison 40. Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

21

Mean Difference (IV, Fixed, 95% CI)

0.92 [‐1.25, 3.09]

Figuras y tablas -
Comparison 40. Levonorgestrel 250 µg and EE 50 µg versus norethisterone acetate 1 mg and EE 50 µg
Comparison 41. Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 3) Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

0.09 [‐1.15, 1.33]

Figuras y tablas -
Comparison 41. Levonorgestrel and EE 6‐6‐9 day regimen versus levonorgestrel 6‐5‐10 day regimen
Comparison 42. Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2.5 kg (cycle 12) Show forest plot

1

228

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.75 [0.98, 3.11]

2 Lost >2.5 kg (cycle 12) Show forest plot

1

228

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.66 [0.25, 1.77]

Figuras y tablas -
Comparison 42. Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg
Comparison 43. Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

144

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐0.70, 0.90]

Figuras y tablas -
Comparison 43. Norethisterone 500‐1000 µg and EE 35 µg versus levonorgestrel 50‐75‐125 µg and EE 30‐40 µg
Comparison 44. Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

349

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.15 [0.65, 2.06]

2 Mean body mass percentage change (cycle 6) Show forest plot

1

45

Mean Difference (IV, Fixed, 95% CI)

‐0.5 [‐2.51, 1.51]

Figuras y tablas -
Comparison 44. Norgestimate 250 µg and EE 35 µg versus desogestrel 150 µg and EE 30 µg
Comparison 45. Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gained >2 kg (cycle 6) Show forest plot

1

292

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.09 [0.60, 1.99]

2 Lost >2 kg (cycle 6) Show forest plot

1

292

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.69 [0.89, 3.20]

Figuras y tablas -
Comparison 45. Norethisterone 500 µg and EE 20 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 46. Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 6) Show forest plot

1

5328

Mean Difference (IV, Fixed, 95% CI)

0.26 [0.12, 0.40]

Figuras y tablas -
Comparison 46. Norethindrone 500‐750‐1000 µg and EE 35 µg versus desogestrel 100‐125‐150 µg and EE 25 µg
Comparison 47. Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Weight gain >=5% (cycle 6) Show forest plot

1

2157

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.15 [0.91, 1.45]

2 Weight gain >=5% (cycle 13) Show forest plot

1

453

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.09 [0.69, 1.74]

3 Weight loss >=5% (cycle 6) Show forest plot

1

2157

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.72, 1.37]

4 Weight loss >=5% (cycle 13) Show forest plot

1

453

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.32 [0.74, 2.34]

Figuras y tablas -
Comparison 47. Norgestimate 180‐215‐250 µg and EE 25 µg versus norethindrone acetate 1 mg and EE 20 µg
Comparison 48. Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

1.8 [‐0.73, 4.33]

Figuras y tablas -
Comparison 48. Standard norgestrel and EE regimen versus prolonged norgestrel and EE regimen
Comparison 49. Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 12) Show forest plot

1

3029

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.04, 0.30]

Figuras y tablas -
Comparison 49. Injectable medroxyprogesterone acetate 25 mg and EC 5 mg versus norethisterone enanthate 50 mg and EV 5 mg
Comparison 50. Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gain >2 kg (cycle 4) Show forest plot

1

51

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.69 [0.13, 3.58]

2 Lost >2 kg (cycle 4) Show forest plot

1

51

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.69 [0.35, 8.07]

Figuras y tablas -
Comparison 50. Vaginal ring with norethindrone acetate 1 mg and EE 15 µg versus norethindrone acetate 1 mg and EE 20 µg
Comparison 51. Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Gain >=7% body weight (cycle 13) Show forest plot

1

1030

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.84 [0.55, 1.28]

2 Lost >=7% body weight (cycle 13) Show forest plot

1

1030

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.39 [0.83, 2.32]

Figuras y tablas -
Comparison 51. Vaginal ring etonogestrel 120 µg and EE 15 µg versus levonorgestrel 150 µg and EE 30 µg
Comparison 52. Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean weight change in kg (cycle 13 or last assessment) Show forest plot

1

937

Mean Difference (IV, Fixed, 95% CI)

0.4 [0.03, 0.77]

Figuras y tablas -
Comparison 52. Vaginal ring etonogestrel 120 µg and EE 15 µg versus drospirenone 3 mg and EE 30 µg